You are here

Erbitux®

An antibody based therapy presenting synergism with conventional chemotherapy. The synergistic effect was invented at the Weizmann Institute. Erbitux was developed by ImClone Systems and approved by the FDA in 2001.Imclone has a license to the synergism patent. Erbitux Sales in 2007 exceeded 1B$.

Erbitux is an antibody based therapy presenting synergism with conventional chemotherapy. 

  • The synergistic effect was invented 
    by Prof. Sela’s group at WIS between 1987-88.
  • Erbitux was developed by ImClone Systems & approved by the FDA in 2001.
  • Ongoing phase III studies in several new indications (e.g. CRC, SCCHN, NSCLC)
  • Estimated yearly sales - $1 billion.